Pre-Test HER2-Positive Breast Cancer: Establishing Proper Sequences Through Clinical Pathways Pre-Test Which of the following is the preferred regimen for patients with CNS progression, according to current NCCN guidelines? Capecitabine + trastuzumab or lapatinib Pertuzumab + trastuzumab + docetaxel Trastuzumab + docetaxel + vinorelbine Tucatinib + trastuzumab + capecitabine Unsure Studies have shown the value of clinical pathways in oncology; on-pathway treatment costs ____ less than off-pathway treatment. 5% to 15% 10% to 25% 15% to 35% 20% to 40% Unsure Please rate your level of confidence in translating the latest evidence, expert recommendations, and available cost data into improved breast cancer clinical pathway development. Excellent Very good Good Fair Poor How frequently does your practice utilize systems in its day-to-day operations that integrate evidence-based guidelines for HER2+ breast cancer diagnosis, treatment, and follow-up care? Always Often Sometimes Rarely Never
